Publications by authors named "Emmanuelle Dochy"

Claim this Profile
R
Real-world testing of serum lactate dehydrogenase among patients with metastatic colorectal cancer in the United States.
Heinz-Josef Lenz, Orsolya Lunacsek, Helene Ostojic, Xiaoyun Pan, Emmanuelle Dochy

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials.
Angélique Vienot, Dewi Vernerey, Adeline Bouard, Elodie Klajer, Stefano Kim, Emmanuelle Dochy

Cancer Res Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial.
Giuseppe Pasqualetti, Marta Schirripa, Emmanuelle Dochy, Matteo Fassan, Pina Ziranu

Eur J Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Michel Ducreux, Lone Nørgård Petersen, Leopold Öhler, Francesca Bergamo, Jean-Philippe Metges, Emmanuelle Dochy

Eur J Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Paul Ruff, Eric Van Cutsem, Radek Lakomy, Jana Prausova, Guy A van Hazel, Emmanuelle Dochy

J Geriatr Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Eric Van Cutsem, Florence Joulain, Paulo M Hoff, Edith Mitchell, Paul Ruff, Emmanuelle Dochy

Target Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of pretest probability of pulmonary embolism in the emergency department by physicians in training using the Wells model.
Andrea Penaloza, Christian Mélot, Emmanuelle Dochy, Didier Blocklet, Pierre Alain Gevenois

Thromb Res· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[News in the medical treatment of breast cancer].
Martine Piccart, Emmanuelle Dochy, Fatima Cardoso

Bull Cancer· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis